BRCA1 and posterior cortical atrophy: Similar to homologous recombination-deficient (HRD) ovarian and pancreatic cancers, PCa with mutations in key HR genes (including BRCA1/2, PALB2, CHEK1/2, and ATM) demonstrate sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors.